See today's BioWorld Asia
To read the full story, subscribe or sign in.

Head to head: Beigene’s BTK inhibitor yields solid data against Imbruvica

May 4, 2021
By Lee Landenberger
Beigene Ltd.’s selective inhibitor, Brukinsa (zanubrutinib), made up for a 2019 miss in a head-to-head study against Johnson & Johnson and Abbvie Inc.’s Imbruvica (ibrutinib) with positive new data from a phase III trial.
BioWorld Asia Clinical Cancer